Search Results

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the second quarter ended March 31, 2022.

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests announced that the Company’s board of directors has issued layoff notices to each of Andrew Morris, the Company’s Chief Executive, and Eric Brouwer, the Company’s Chief Scientific Officer, in an effort to further reduce the Company’s expenses.

SQI Diagnostics Inc. announced it is developing three diagnostic products based on University Health Network innovations and is exploring an initiative with Owlstone Medical and UHN on a fourth diagnostic product.

SQI Diagnostics Inc. today announces that it has entered into a new consulting agreement with Looking Glass Capital Consultants.

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests reported its financial and operational results for the first quarter ended December 31, 2022.

SQI Diagnostics Inc. announced that the Company’s board of directors has received a notice of intention to enforce security issued by its senior secured creditor, Pivot Financial I Limited Partnership, under Section 244 of the Bankruptcy and Insolvency Act.

SQI Diagnostics Inc. announces that certain insiders of the Company, who are also control persons of the Company and collectively own, or exercise control or direction over, an aggregate of 75% of the issued and outstanding common shares.

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

SQI Diagnostics Inc., a leader in the science of lung health, announced that it is moving to strategically focus on what is now its core business: creating precision Point of Care products in respiratory health.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD) (OTCQB: SQIDF) today announced that it has entered into a funding agreement (the “Contribution Agreement”) with the Federal Economic Development Agency for Southern Ontario (“FedDev Ontario”) to support the Company’s manufacturing scale-up and commercialization of its pipeline of products in development, including the Company’s recently approved RALI-DX IL-6 test.